28.4 C
Vientiane
Sunday, August 24, 2025
spot_img
Home Blog Page 42

NYSE Content Advisory: Pre-Market Update + Retail Earnings Kick Off

NEW YORK, Aug. 19, 2025 /PRNewswire/ — The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today’s NYSE Pre-market update for market insights before trading begins. 

 

NYSE Content Advisory: Pre-Market Update + Retail Earnings Kick Off

Ashley Mastronardi delivers the pre-market update on August 19th

  • Stocks are mixed after Monday saw little change to the major averages. The retail sector will make headlines today as NYSE-listed Home Depot released earnings ahead of market open.
  • Investors will be keeping a close eye on the numbers to gauge how the consumer is faring amid inflation and trade policy uncertainty.
  • Investors are bracing for what the Fed says later this week at its annual Economic Policy Symposium at Jackson Hole, Wyoming. Chair Powell will deliver his remarks on Friday.

Opening Bell
EB Research Partnership celebrates three FDA-approved treatments for EB in the pursuit of a cure

Closing Bell
Action Against Hunger honors our 8,900+ staff worldwide

Click here to download the NYSE TV App

Video – https://mma.prnasia.com/media2/2753599/NYSE_Market_Update_Aug_19.mp4

 

WuXi Biologics Reports Solid 2025 Interim Results

  • Revenue increased by 16.1% YoY to RMB 9,953.2 million; revenue growth from continuing operations was 20.2%
  • IFRS Gross profit margin expanded by 3.6% YoY to 42.7%
  • EBITDA grew 50.5% YoY and IFRS net profit increased 54.8% YoY
  • Adjusted EBITDA grew 20.6% YoY and adjusted net profit increased 11.6% YoY
  • FY25 group revenue growth target raised to 14% – 16%
  • A first-half record of 86 new integrated projects added, including 2 in late-stage
  • Total integrated projects reached 864, one of the largest portfolios of complex biologics
  • Late-stage and CMO revenue rose 24.9% YoY; 25 PPQs scheduled for 2025
  • Total backlog increased to US$20.34 billion; backlog within 3 years increased to US$4.21 billion
  • Optimized global operations and enhanced capacities to support sustainable growth

HONG KONG, Aug. 19, 2025 /PRNewswire/ — WuXi Biologics (Cayman) Inc. (“WuXi Biologics” or “the Group”, stock code: 2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) service company offering end-to-end solutions for biologics discovery, development and manufacturing, is pleased to announce its unaudited interim results for the first half of 2025 (“Reporting Period”).

Financial Highlights

Revenue: The Group’s revenue for the Reporting Period increased by 16.1% YoY to RMB9,953.2 million. The growth was primarily driven by: (i) the continued success of the Group’s “Follow and Win the Molecule” strategies, supported by its leading technology platforms, best-in-industry timelines and strong execution record; (ii) an expanded range of services offered across the biologics value chain – including discovery, pre-IND development, and clinical and commercial manufacturing – with notable momentum in fast-growing platforms such as antibody-drug conjugates (ADCs), and bi- & multi-specific antibodies; (iii) growth in research services revenue, underpinned by the Group’s cutting-edge technologies; and (iv) increased utilization of both existing and newly expanded capacity, including the ramp-up of the Group’s manufacturing facility in Europe.

Gross Profit and Gross Profit Margin: IFRS gross profit increased 27.0% YoY to RMB4,252.9 million, while adjusted gross profit rose 19.2% YoY to RMB4,543.4 million. IFRS gross profit margin reached 42.7%, with adjusted gross profit margin at 45.6%. The improvement in gross profit margin was primarily driven by favorable volume and mix, enhanced efficiency and process optimization achieved through the Group’s WBS and digitalization initiatives.

EBITDA and EBITDA Margin: EBITDA grew 50.5% to RMB4,221.8 million, while adjusted EBITDA increased 20.6% YoY to RMB4,305.2 million. EBITDA margin reached 42.4%, and adjusted EBITDA margin expanded to 43.3%.

Net Profit and Net Profit Attributable to Owners of the Company: IFRS net profit rose 54.8% YoY to RMB2,756.6 million, while net profit attributable to owners of the Company grew 56.0% to RMB2,339.3 million. This growth was primarily driven by higher gross profit, the gains from the Group’s investment and asset divestiture activities.

Adjusted Net Profit: Adjusted Net Profit for the period increased 11.6% YoY to RMB2,840.0 million, with an adjusted net profit margin of 28.5%.

Basic Earnings Per Share (EPS): Basic EPS rose 56.8% from RMB 0.37 for the six months ended June 30, 2024 to RMB 0.58 for the six months ended June 30, 2025. Diluted EPS increased by 57.1% from RMB 0.35 to RMB 0.55 over the same period.

Business Highlights

  • Integrated Project Wins

The Group added 86 integrated projects in the first half of 2025, bringing the total to 864. Over half of these new projects were originated from U.S. clients, reflecting continued client trust and the resilience of the Group’s CRDMO business model amid ongoing market volatility. The Group supports 67 late-stage and 24 commercial projects, establishing a strong foundation for sustained future manufacturing revenue growth.

Of the 86 new projects, 9 were post-IND wins under the Group’s “Win-the-Molecule” strategy, including 2 in late-stage. Most of these involve complex modalities such as bi- and multi-specific antibodies, and ADCs.

  • Research

Building on its industry-leading technology platforms and growing global recognition, the Group’s Research business maintained strong momentum in the first half of 2025. Ongoing partnerships with global innovators continued to advance discovery programs across bi- and multi-specific TCEs and ADCs. These collaborations reflect strong client trust and further expand the Group’s biologics pipeline. Notably, a molecule developed for GSK recently entered clinical trials, becoming the fourth WuXi Biologics–originated TCE to reach the clinic stage. To date, the Group’s Research Services has enabled 50+ programs that are potentially eligible for future milestone payments and sales royalties, unlocking significant upside for the Group’s long-term profitable growth.

  • Development

The Group added a first-half record of 86 new integrated development projects in the first half of 2025, further expanding one of the industry’s largest portfolios of complex biologics. Bi- & multi-specifics, along with ADCs, accounted for over 70% of new signs, expanding our portfolio to 168 bi- & multispecifics, 225 ADCs, 80 fusion proteins, 25 vaccines and 326 mAbs – highlighting the Group’s strong execution and leadership in next-generation modalities.

During the Reporting Period, the Group’s pre-IND revenue rose 35.2% YoY, driven by revenue conversion of wins across Research services and pre-IND development. Supported by the Group’s proprietary cell line development platform WuXiaTM, over 600 projects with potential cell line royalty are expected by the end of 2025. Amid continued momentum in innovative drug out-licensing from China, the Group remained a critical partner in global biopharma discovery and development collaborations, supported by its industry-leading technology platforms and operational excellence.

During the Reporting Period, the Group launched WuXiHigh™2.0, its next-generation high-throughput formulation platform for high concentration biologics. By leveraging proprietary excipient blends and formulation expertise, the platform enables protein concentrations of up to 230 mg/mL and reduces viscosity by up to 90% – while preserving stability and injectability. This innovative platform reflects the Group’s ongoing commitment to technological advancement and empowers clients to accelerate development and enhance patient delivery.

  • Manufacturing

As of June 30, 2025, the Group has supported 67 late-stage projects and 24 commercial manufacturing projects, and remains on track to complete 25 scheduled process performance qualification (PPQ) campaigns in 2025. During the Reporting Period, late-phase and commercial manufacturing revenue increased by 24.9% YoY, reflecting both evolution of projects from early-phases and the continued ramp-up of existing CMO programs. To meet the growing commercial demands and ensure supply chain reliability, the Group continues to implement its “Global Dual Sourcing” strategy by expanding capacity and capabilities across its global manufacturing network:

    • Ireland: MFG6.2 successfully released three 1,000L single-use bioreactor systems, increasing total perfusion capacity from 3,000L to 6,000L. The first engineering and PPQ runs were both successfully completed during the Reporting Period. Meanwhile, MFG7 completed its second 12,000L PPQ run. In addition, MFG6 recently received its first EMA approval as a commercial manufacturing site for a global client’s innovative biologic, underscoring the consistency and strength of WuXi Biologics’ quality systems. To date, the Ireland site has maintained a 100% success rate for all PPQ runs.
    • Singapore: Construction has begun on a new modular drug product (DP) facility, while design work is underway for a planned drug substance (DS) modular facility within the CRDMO hub. Additionally, mechanical completion was achieved at the XDC manufacturing site. Operations are expected to commence by the end of 2025, with GMP manufacturing to follow in early 2026. The Group is making solid strides according to the planned schedule to establish Singapore as another strategic hub for our global biologics Research, Development and Manufacturing services.
    • U.S: Construction at MFG11 (Worcester, MA) is advancing, with the facility designed to house six 6,000L single-use bioreactors connected to a single downstream line, enabling high-throughput processing and advanced automation. Once operational, MFG11 will be seamlessly integrated with MFG18 (Cranbury, NJ), and the Boston Research Service Center, enhancing the Group’s ability to deliver end-to-end services across Research, Development, and Manufacturing in the U.S. This build-out further strengthens the Group’s global footprint and reinforces its commitment to serving clients closer to key innovation and commercial markets.
    • Chengdu, China: Construction began on a new microbial manufacturing facility, featuring a 15,000L fermenter and scalable capacity up to 60,000L. The site will utilize the recently launched EffiX™ microbial expression platform to deliver high-yield, consistent, and scalable production of biologics.
    • Hangzhou, China: The first commercial PPQ campaign was completed at the 15,000L line in MFG20 – Asia’s first 5,000L drug substance scale-out line using single-use bioreactors (SUBs). This achievement underscores the Group’s advanced capabilities in leveraging single-use systems for large-scale commercial manufacturing.
  • Asset Optimization 

During the Reporting Period, the Group executed two strategic transactions aimed at optimizing global operations and improving asset efficiency. The asset transfer of WuXi Vaccines’ facility in Dundalk, Ireland to MSD International GmbH, was completed in March 2025. In May 2025, the Group entered into a definitive agreement to divest its DP facility in Leverkusen, Germany to Terumo Corporation. The transaction enables the Group to reallocate resources toward scaling large-scale DP manufacturing capabilities in Singapore. The divestment supports greater operational agility, improved asset efficiency, and the continued expansion of diversified solutions for global clients. The transaction is expected to close in the fourth quarter of 2025.

  • Backlog

As of Jun 30, 2025, total backlog increased to US$20.34 billion, comprising US$11.35 billion service backlog and US$9.0 billion of potential milestone payments. Backlog within 3 years increased to US$4.21 billion from US$3.65 billion as of December 2024, enhancing near-term revenue visibility.

  • Quality

The Group remains steadfast in its commitment to quality, ensuring the protection of client and partner interests through a globally recognized quality management system. Since 2017, the Group has successfully completed 44 regulatory inspections by major national authorities — including 22 by the U.S. FDA and EU EMA — with no critical issues and zero data integrity findings. All five manufacturing facilities in Wuxi, China — including MFG1 and MFG5 (drug substance), and DP1, DP2, and DP5 (drug product) — also successfully passed U.S. FDA Pre-License Inspections (PLI). This achievement reinforces the Group’s consistent 100% PLI pass rate and highlights its uncompromising adherence to global quality standards.

  • Talents

As of June 30, 2025, the Group’s global workforce reached 12,552 employees, including 4,362 scientists, with a key talent retention rate of 98.8%. Effective global recruitment and talent development efforts have further strengthened our operational execution across regions, enabling timely project delivery and fueling ongoing innovation.

  • WBS (WuXi Biologics Business System)

Introduced in 2021 and implemented across all business units and functions, WBS continues to drive operational excellence by improving efficiency, enhancing quality, and reducing costs – delivering greater value to clients.

During the Reporting Period, the Group executed approximately 130 Kaizen projects and events, contributing to a 100-basis point improvement in gross profit margin. These initiatives also supported business growth, improved labor efficiency, lowered costs, and enhanced quality outcomes.

In parallel, ESG-focused Kaizen projects advanced the Group’s sustainability goals, achieving meaningful reductions in carbon emissions, water consumption, waste generation, and energy usage. The Group remains committed to deepening WBS adoption, fostering a culture of continuous improvement, and enhancing long-term value creation through innovation and talent development.

  • Sustainability 

Sustainability remains a cornerstone of the Group’s long-term strategy, closely integrated with its corporate vision and mission. During the Reporting Period, the Group achieved meaningful progress across key ESG pillars and received broad recognition from leading global rating agencies.

Notable accolades include inclusion in the Dow Jones Sustainability Indices, AAA ESG Ratings from MSCI, selection into MSCI ESG Indexes, and the EcoVadis Platinum Medal. The Group also earned the highest negligible-risk rating from Sustainalytics and was recognized as both an Industry and Regional ESG Top-Rated Company. Additional honors include placement on CDP’s Water Security and Supplier Engagement “A List”, as well as an A- score for CDP Climate Change, reflecting leadership in environmental transparency and actions.

Management Comment

Dr. Chris Chen, CEO of WuXi Biologics, stated, “In the first half of 2025, we achieved solid and profitable growth, delivering a 16.1% YoY increase in Group revenue and expanding operating margin while navigating the macroenvironment. M revenue grew 24.9% YoY, with 25 PPQs scheduled for 2025. 86 new integrated projects were added during the Reporting Period, a record first-half. Our unique CRDMO business model, together with the disciplined execution of our ‘Follow and Win the Molecule’ strategies, enabled us to capture new business opportunities, accelerate client pipelines, and deepen long-term partnerships.” 

Dr. Chen added, “Combining WBS with ongoing investments in advanced technologies and digital platforms, we are enhancing efficiency, accelerating execution, and driving innovation. We are also strengthening our global footprint and reinforcing our commitment to serving clients closer to centers of innovation and key commercial markets. We remain committed to the highest standards of compliance while enabling our clients and partners to bring innovative biologics to patients worldwide. Our strong first-half results boost our confidence in delivering accelerated growth and support a revenue target increase.”

Dr. Ge Li, Chairman of WuXi Biologics, concluded, “WuXi Biologics demonstrated resilience and delivered solid performance in the first half of 2025. Guided by our client-first philosophy and supported by our fully integrated open-access platform, we continue to advance global biopharmaceutical discovery, development, and manufacturing. Looking ahead, we remain committed to creating greater value for clients and better outcomes for patients, as we pursue our vision that ‘every biologic can be made’.”

Key Financial Ratios

(For the Six Months Ended June 30)

Key Financial Ratio

1H 2025

1H 2024

Change

Revenue (In RMB million)

9,953.2

8,574.2

16.1 %

Gross Profit (In RMB million)

4,252.9

3,350.0

27.0 %

Margin (%)

42.7 %

39.1 %

Net Profit (In RMB million)

2,756.6

1,780.3

54.8 %

Margin (%)

27.7 %

20.8 %

Net Profit Attributable to Owners of the
Company (In RMB million)

2,339.3

1,499.1

56.0 %

Margin (%)

23.5 %

17.5 %

Adjusted Net Profit (In RMB million)

2,840.0

2,544.8

11.6 %

Margin (%)

28.5 %

29.7 %

EBITDA (In RMB million)

4,221.8

2,805.9

50.5 %

Margin (%)

42.4 %

32.7 %

Adjusted EBITDA (In RMB million)

4,305.2

3,570.4

20.6 %

Margin (%)

43.3 %

41.6 %

Adjusted Basic EPS (In RMB)

0.59

0.55

7.3 %

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.

With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of June 30, 2025, WuXi Biologics is supporting 864 integrated client projects, including 24 in commercial manufacturing.

WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives green technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while consistently achieving excellence in Environment, Social and Governance (ESG). Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts and promote responsible practices that empower the entire value chain.

For more information about WuXi Biologics, please visit: www.wuxibiologics.com.

Forward-Looking Statements

This announcement may contain certain “forward-looking statements” that are not historical facts, but instead are predictions about future events based on our expectations as well as assumptions made by and information currently available to our management. Although we believe that our predictions are reasonable, future events are inherently uncertain and our forward-looking statements may turn out to be incorrect. Our forward-looking statements are subject to risks relating to, among other things, the ability of our service offerings to compete effectively, our ability to meet timelines for the expansion of our service offerings, and our ability to protect our clients’ intellectual property. Our forward-looking statements in this announcement speak only as of the date on which they are made, and we assume no obligation to update any forward-looking statements except as required by applicable law or listing rules. Accordingly, you are strongly cautioned that reliance on any forward-looking statements involves known and unknown risks and uncertainties. All forward-looking statements contained herein are qualified by reference to the cautionary statements set forth in this section.

Non-IFRS Measures

To supplement the Group’s condensed consolidated financial statements which are presented in accordance with the IFRS, the Company has provided adjusted net profit, adjusted net profit margin, adjusted EBITDA, adjusted EBITDA margin and adjusted basic and diluted earnings per share as additional financial measures, which are not required by, or presented in accordance with, the IFRS.

The Company believes that the adjusted financial measures are useful for understanding and assessing underlying business performance and operating trends, and that the Company’s management and investors may benefit from referring to these adjusted financial measures in assessing the Group’s financial performance by eliminating the impact of certain unusual, non-recurring, non-cash and/or non-operating items that the Group does not consider indicative of the performance of the Group’s core business. These non-IFRS financial measures, as the management of the Group believes, is widely accepted and adopted in the industry in which the Group is operating in. However, the presentation of these non-IFRS financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with the IFRS. Shareholders of the Company and potential investors should not view the adjusted results on a stand-alone basis or as a substitute for results under IFRS. And these non-IFRS financial measures may not be comparable to similarly-titled measures represented by other companies.

Contacts

Media
PR@wuxibiologics.com 

Investors
IR@wuxibiologics.com

 

 

Saudi Arabian Cricket Federation and National Cricket League Team Up to Grow Grassroots Cricket and Develop Future Stars

Partnership to boost grassroots cricket, highlight the Collegiate Cricket League and Path to Cricket Pro, and build pathways to the world stage

DALLAS, Aug. 19, 2025 /PRNewswire/ — With cricket set to make its return to the Olympics at the Los Angeles 2028 Games, the National Cricket League (NCL) and the Saudi Arabian Cricket Federation (SACF) have joined to expand grassroots cricket programs, create elite player pathways, and connect two of the sport’s fastest-growing markets.

The partnership reflects ICC Chairman Jay Shah’s focus on building cricket in associate nations by engaging passionate diaspora communities and attracting new fans. Both the United States and Saudi Arabia share similar cricket growth trajectories, and this collaboration will develop sustainable programs that take players from local pitches to international competition.

Under the agreement, the two organizations will work together in four key areas:

  • Grassroots Development – Creating school, academy, and community cricket programs; hosting tournaments and clinics; and building pathways for young talent to progress to the highest levels of the game.
  • Knowledge & Expertise Sharing – Exchanging best practices in infrastructure, coaching, league operations, and player development.
  • Technical Collaboration – Establishing coaching certification pathways, setting umpiring standards, and implementing digital training tools.
  • Events & Exposure – Offering Saudi grassroots players opportunities to participate in NCL development events, including the Collegiate Cricket League — a leading university-level competition — and the upcoming Path to Cricket Pro talent hunt, designed to scout and prepare the next wave of professional cricketers.

The partnership will also create opportunities for young, emerging Saudi cricketers by providing them a platform to participate in NCL tournaments across the USA and Canada, while building the future of cricket together between both nations.

“This is a bridge connecting two nations with a shared passion for cricket and a vision for its future,” said Arun Agarwal, Chairman of the National Cricket League. “By aligning our grassroots systems and opening cross-border pathways, we’re creating real opportunities for young players to move from local pitches to the world stage.”

Saudi Arabia is experiencing a surge in cricket participation, and this cooperation with the National Cricket League allows us to turn that momentum into structured grassroot development programs and international opportunities,” said Tariq Sagga, CEO of the Saudi Arabian Cricket Federation. “Together, we can inspire the next generation and grow the sport’s global footprint.”

The NCL–SACF collaboration shows how strategic partnerships can expand cricket’s reach, raise playing standards, and connect communities through sport.

Media Contact: Media@NCLCricket.com | + 1(214)-945-4172
Malharbi@saudicricket.sa | +966 54 478 8443

 

HT Materials Science Delivers Substantial Energy Savings for DKSH Malaysia

Installing Maxwell® led to a 13% reduction in chiller energy consumption and projected annual savings of 600,000 kWh

DUBLIN, Aug. 19, 2025 /PRNewswire/ — HT Materials Science (HTMS), a global leader in cooling technology, has successfully implemented its breakthrough heat-transfer fluid, Maxwell®, at a pharmaceutical cold storage facility operated by DKSH Malaysia. The installation resulted in significant energy savings, operational improvements and system performance—positioning the project as one of Southeast Asia’s most effective commercial HVAC retrofits to date.

Created by suspending sub-micron particles of aluminum oxide in a base fluid of water or glycol, Maxwell is a non-toxic, fully recyclable additive that enhances heat transfer in industrial HVAC systems. That improved heat transfer reduces energy consumption while increasing system capacity. For the DKSH Malaysia project, adding Maxwell led to a 13 percent reduction in the chiller’s energy consumption, for a projected annual savings of 600,000 kilowatt hours and a payback period of 2.1 years. This installation was procured and engineered by Tri Quantity Sdn Bhd, an energy management and audit company based in Malaysia.

Based on energy savings alone, the payback period for this project is projected at just over two years. It’s a welcome innovation for a facility with strict temperature and humidity needs and regulations, as installing Maxwell® requires no system downtime. In addition to energy savings, DKSH expects reduced wear and tear on the facility’s HVAC equipment, longer system lifespan and lower maintenance costs due to reduced scaling and improved fluid dynamics.

“This installation demonstrates that smart, science-driven HVAC technologies can deliver immediate cost savings and long-term sustainability benefits,” said Thomas Grizzetti, CEO of HTMS. “We’re proud to partner with forward-thinking companies like Tri Quantity and DKSH who are helping to set the standards for energy efficiency in large-scale commercial facilities.”

“This initiative not only strengthens our operational efficiency but also reaffirms DKSH’s commitment to sustainable, future-focused business practices,” said Joel Solomon, Head, Supply Chain Management, DKSH Malaysia & Brunei.

This project provides a compelling blueprint for how commercial facilities can unlock measurable energy gains through smart retrofits. The results are applicable across industries including logistics, education, retail and data centers. HTMS contracts include performance guarantees, with minimum savings thresholds and annual reconciliation.

“What makes this so compelling is the speed at which results materialized,” added Grizzetti. “Within weeks, we saw verified energy savings—demonstrating just how accessible and impactful these upgrades can be for building operators anywhere in the world.”

About DKSH

For 160 years, DKSH has been delivering growth for companies in Asia and beyond across its Business Units Healthcare, Consumer Goods, Performance Materials, and Technology. As a leading Market Expansion Services provider, DKSH offers sourcing, market insights, marketing and sales, eCommerce, distribution and logistics as well as after-sales services, following its purpose of enriching people’s lives. DKSH is a participant of the United Nations Global Compact and adheres to its principles-based approach to responsible business. Listed on the SIX Swiss Exchange, DKSH operates in 36 markets with 28,060 specialists, generating net sales of CHF 11.1 billion in 2024. www.dksh.com

About HT Materials Science

Based in Ireland, HTMS is dedicated to developing sustainable energy savings solutions aimed at improving the efficiency of HVAC systems in commercial and industrial sectors. HTMS was included this year in Fast Company’s list of Most Innovative Companies. The company’s flagship product, a heat-transfer fluid called Maxwell, is designed to enhance heat transfer and significantly reduce energy consumption, helping companies meet sustainability goals and combat climate change. https://htmaterialsscience.com/

About Tri Quantity

Based in Selangor, Tri Quantity provides energy management and audit services in Malaysia, Singapore and Asia. Tri Quantity is the exclusive distributor of Maxwell in the region. https://www.triquantity.com/

 

HT Materials Science Delivers Substantial Energy Savings for DKSH Malaysia Installing Maxwell® led to a 13% reduction in chiller energy consumption and projected annual savings of 600,000 kWh

DUBLIN, Aug. 19, 2025 /PRNewswire/ — HT Materials Science (HTMS), a global leader in cooling technology, has successfully implemented its breakthrough heat-transfer fluid, Maxwell®, at a pharmaceutical cold storage facility operated by DKSH Malaysia. The installation resulted in significant energy savings, operational improvements and system performance—positioning the project as one of Southeast Asia’s most effective commercial HVAC retrofits to date.

Created by suspending sub-micron particles of aluminum oxide in a base fluid of water or glycol, Maxwell is a non-toxic, fully recyclable additive that enhances heat transfer in industrial HVAC systems. That improved heat transfer reduces energy consumption while increasing system capacity. For the DKSH Malaysia project, adding Maxwell led to a 13 percent reduction in the chiller’s energy consumption, for a projected annual savings of 600,000 kilowatt hours and a payback period of 2.1 years. This installation was procured and engineered by Tri Quantity Sdn Bhd, an energy management and audit company based in Malaysia.

Based on energy savings alone, the payback period for this project is projected at just over two years. It’s a welcome innovation for a facility with strict temperature and humidity needs and regulations, as installing Maxwell® requires no system downtime. In addition to energy savings, DKSH expects reduced wear and tear on the facility’s HVAC equipment, longer system lifespan and lower maintenance costs due to reduced scaling and improved fluid dynamics.

“This installation demonstrates that smart, science-driven HVAC technologies can deliver immediate cost savings and long-term sustainability benefits,” said Thomas Grizzetti, CEO of HTMS. “We’re proud to partner with forward-thinking companies like Tri Quantity and DKSH who are helping to set the standards for energy efficiency in large-scale commercial facilities.”

“This initiative not only strengthens our operational efficiency but also reaffirms DKSH’s commitment to sustainable, future-focused business practices,” said Joel Solomon, Head, Supply Chain Management, DKSH Malaysia & Brunei.

This project provides a compelling blueprint for how commercial facilities can unlock measurable energy gains through smart retrofits. The results are applicable across industries including logistics, education, retail and data centers. HTMS contracts include performance guarantees, with minimum savings thresholds and annual reconciliation.

“What makes this so compelling is the speed at which results materialized,” added Grizzetti. “Within weeks, we saw verified energy savings—demonstrating just how accessible and impactful these upgrades can be for building operators anywhere in the world.”

About DKSH

For 160 years, DKSH has been delivering growth for companies in Asia and beyond across its Business Units Healthcare, Consumer Goods, Performance Materials, and Technology. As a leading Market Expansion Services provider, DKSH offers sourcing, market insights, marketing and sales, eCommerce, distribution and logistics as well as after-sales services, following its purpose of enriching people’s lives. DKSH is a participant of the United Nations Global Compact and adheres to its principles-based approach to responsible business. Listed on the SIX Swiss Exchange, DKSH operates in 36 markets with 28,060 specialists, generating net sales of CHF 11.1 billion in 2024. www.dksh.com

About HT Materials Science

Based in Ireland, HTMS is dedicated to developing sustainable energy savings solutions aimed at improving the efficiency of HVAC systems in commercial and industrial sectors. HTMS was included this year in Fast Company’s list of Most Innovative Companies. The company’s flagship product, a heat-transfer fluid called Maxwell, is designed to enhance heat transfer and significantly reduce energy consumption, helping companies meet sustainability goals and combat climate change. https://htmaterialsscience.com/

About Tri Quantity

Based in Selangor, Tri Quantity provides energy management and audit services in Malaysia, Singapore and Asia. Tri Quantity is the exclusive distributor of Maxwell in the region. https://www.triquantity.com/

 

Roborock Launches at Chewy, Offering Smart Cleaning Solutions to Pet Parents

Global Leader in Smart Home Robotics Offers Chewy Customers Robotic Vacuums and Mops at a Discounted Rate in Celebration of the Launch

HONG KONG, Aug. 19, 2025 /PRNewswire/ — Roborock, the #1 selling robot vacuum brand worldwide, is excited to announce that its best-selling robot vacuums and mops, designed to tackle the everyday mess of pet hair, are now available at Chewy, a trusted destination for pet parents and partners everywhere. Known for their powerful suction and intelligent navigation, Roborock’s smart home vacuums effortlessly clean up pet hair, dander, and other messes furry friends leave behind—so you don’t have to.

Roborock & Chewy Partnership
Roborock & Chewy Partnership

As part of this new availability at Chewy, Roborock will be offering exclusive deals on a curated selection of robotic and handheld vacuums, including the Q8 Max, Q10 X5, QV 35A, Qrevo Curv S5X0, and F25. Whether shopping for yourself or a loved one, give the pet parent in your life the gift of a hassle-free, spotless home.

“Roborock is thrilled to bring its ultra-intelligent, smart home cleaning solutions to Chewy’s community of loving pet parents,” said Quan Gang, President of Roborock. “We love our pets, but we know life with them can be messy and our robot vacuums are designed to take the cleanup off your plate. As the demand for hands-free cleaning increases, we’re eager to connect with the passionate Chewy community. We’re excited to see how pet parents integrate Roborock into their routines, giving them more time to enjoy with their furry companions!”

Pet parents can now explore a wide selection of Roborock’s robotic vacuums available at Chewy, including:

  • Roborock Q8 Max: Equipped with Roborock’s most powerful DuoRoller™ Brush System and 5,500Pa suction power, it removes 20% more hair from carpets and prevents hair tangling. LiDAR based navigation curates a detailed map of its surroundings and Reactive Tech Obstacle Avoidance allows the robot to maneuver around common household hazards. MSRP: $599.99, Sale Price: $259.99
  • Roborock F25: Leaving no spot untouched, this handheld vacuum and mop combo has a flat design allowing it to reach under furniture with a 4.92 clearance. The cordless design gives ultimate freedom, while its impressive 20,000Pa suction power effortlessly tackles wet and dry messes. MSRP: $399.99, Sale Price: $349.99
  • Roborock Q10 X5 Series: Featuring 10,000Pa suction power and a JawScrapers Comb anti-tangle main brush and an anti-tangle side brush, this advanced system ensures smooth cleaning and reduced maintenance. In DEEP+ mopping mode, mopping paths are finely divided for a deep, thorough clean to tackle stubborn dirt stains. Q10 X5: MSRP: $359.99, Sale Price: $299.99; Q10 X5+: MSRP: $499,99, Sale Price: $319.99
  • Roborock QV 35A (White): With 8,000Pa suction power and an all-in-one docking station, it delivers ultimate cleaning convenience. The Dual Anti-Tangle System and Reactive Tech Obstacle Avoidance ensures seamless navigation, while Dual Liftable Spinning Mops adapt to any surface. MSRP: $649.99, Sale Price: $439.99
  • Roborock Qrevo Curv S5X: Where elegance meets innovation, the Dual Anti-Tangle System prevents hair clogs for effortless cleaning, while 17,000Pa suction power and the FlexiArm™ Technology ensures every corner is spotless. MSRP: $1,149.99, Sale Price: $949.99

To shop Roborock at Chewy and take advantage of these exclusive launch deals, visit www.chewy.com. For more information on Roborock and to explore additional products, please visit www.us.roborock.com.

About Roborock 

Roborock is a leading smart cleaning brand renowned for its intelligent cleaning solutions. With a steadfast dedication to becoming a global leading smart appliance player, Roborock enriches lives with its innovative line of robotic, cordless, wet/dry vacuum cleaners, and washer-dryers. Rooted in a user-centric approach, our R&D-driven solutions cater to diverse cleaning needs in over 15 million homes across 170+ countries. Headquartered in Beijing and with strategic subsidiaries in key markets, including the United States, Japan, the Netherlands, Poland, Germany, and South Korea, Roborock is dedicated to elevating its market presence worldwide. For more information, visit https://global.roborock.com/

Media Contact:
Marisa Lapointe
Rachel Kay Public Relations
a FINN Partners Company
925-407-6438
marissa.lapointe@finnpartners.com

HTX July Report: Tops Global Exchange Ranking in Trading Volume Growth, New Listing Delivers 25x Return

PANAMA CITY, Aug. 19, 2025 /PRNewswire/ — HTX, a leading global crypto exchange, achieved standout growth during July’s market rally, with significant increase in new users, trading volume, and stunning returns on new listings. The exchange demonstrated comprehensive upgrades across products, branding, security, and services, showcasing robust growth momentum and operational excellence.


Trading Volume Growth Ranks No.1 Among Top Exchanges

According to CoinGecko’s latest Q2 exchange report, HTX topped global rankings for trading volume growth, significantly outperforming industry averages. Additionally, CoinDesk’s July exchange market share report noted that HTX achieved the second-largest market share increase year-to-date, trailing only Binance—cementing its place among the top-tier global trading platforms.


In July, HTX achieved remarkable performance metrics, including a 45% surge in new user registrations and 33% growth in trading volume month-over-month. HTX’s native growth engine keeps firing on all cylinders, propelled by surging organic traffic and industrial rankings that are fostering an increasingly vibrant ecosystem.

HTX listed 12 new assets in July spanning AI, meme coin, and layer 1 sectors. Among them, token M debuted exclusively on the platform and soared as much as 25x, creating a significant wealth effect for early participants. The AI-focused ANI, buoyed by comments from Elon Musk, quickly became the hottest on-chain project in the humanoid AI category, posting a peak gain of 426% after listing. Other additions such as BLUM and COOKIE broadened HTX’s exposure to high-growth sectors.

HTX New Listing Winners
HTX New Listing Winners

Campaigns Drive Liquidity and Brand Reach

On the marketing operations front, HTX ran campaigns exclusive to stablecoins, centered on USD1, USDC, and USDD, generating over $400 million in spot trading volume. Additionally, the HTX 12th-Anniversary Carnival has begun and will run until September 12. Participants can light up “Task Planets” to earn rewards, including trading fee rebate vouchers, 0% margin interest vouchers, token airdrops, merchandise, and entries into lucky draws with grand prizes of 120 million $HTX and a $2,000 travel fund.

During Istanbul Blockchain Week, HTX achieved 48+ million impressions in the Turkey market alone, and built deeper ties with partners including 0G Labs, 100xLabs, and Castrum Capital, which facilitated the listing of COOKIE. Online exposure rose by 60.8% versus prior events, with registrations and deposits hitting 14-day highs.

Research and Product Upgrades Strengthen Platform

This July, HTX Research published the first part of its in-depth report “The New Stablecoin Order: Restructuring Global Payments, Regulatory Legitimization, and the Capital War,” offering a macro view of stablecoin dynamics and forward trends.

HTX also launched version 11.0 of its app, redesigning the homepage, assets page, and trading page with overhauled interfaces. Following the upgrade, homepage click-through rates jumped by 24%, streamlining the user experience.

DAO Vision Refreshes with New Whitepaper

HTX DAO released a newly updated Whitepaper, marking a pivotal declaration of strategic direction. The initiative signals HTX’s evolution—from a centralized exchange to a core force in on-chain financial governance—committed to building a user-led “Freeport of Finance.” Under this vision, all participants will not only share in the platform’s growth but also gain genuine decision-making power. Moving forward, the development of HTX DAO will be driven collectively by its community, opening a new chapter that blends decentralized governance with CeFi infrastructure.

Strong Security and Transparent Reserves

As a pioneer in implementing Merkle Tree Proof of Reserves, HTX has consistently demonstrated its dedication to transparency by publicly disclosing reserve data for 34 consecutive months. As of August 1, 2025, all reserve ratios stood at or above 100%, with full transparency via the Assets > PoR Reports section on its website.


From accelerating user and trading growth to delivering standout crypto returns, product innovation, and global brand engagement, the July performance numbers underscore HTX’s ability to execute across multiple fronts. The exchange continues to deepen its user-centric approach and advance product and service innovations to help more traders seize the opportunities of the next market cycle.

About HTX

Founded in 2013, HTX (formerly Huobi) has evolved from a virtual asset exchange into a comprehensive ecosystem of blockchain businesses that span digital asset trading, financial derivatives, research, investments, incubation, and other businesses.

As a world-leading gateway to Web3, HTX harbors global capabilities that enable it to provide users with safe and reliable services. Adhering to the growth strategy of “Global Expansion, Thriving Ecosystem, Wealth Effect, Security & Compliance,” HTX is dedicated to providing quality services and values to virtual asset enthusiasts worldwide.

To learn more about HTX, please visit https://www.htx.com/ or HTX Square , and follow HTX on X, Telegram, and Discord.

Delska’s New 10MW Data Center in Latvia Achieves Tier III Design Certification

RIGA, Latvia, Aug. 19, 2025 /PRNewswire/ — Northern European data center operator Delska’s upcoming facility, EU North Riga LV DC1, has been awarded the prestigious Uptime Institute Tier III Design Certification—an important milestone ahead of its planned launch at the end of this year. Once operational, it will be one of the greenest data centers in the Baltic region.

Delska's new 10MW data center in Latvia achieves Tier III Design Certification
Delska’s new 10MW data center in Latvia achieves Tier III Design Certification

 

The Tier III Design certification ensures the facility meets strict standards for redundancy, safety, and uninterrupted service, guaranteeing 99.982% uptime. “In a world where even a few seconds of downtime can cost thousands, Tier III means our infrastructure stays online—even during planned maintenance,” said Delska CEO Andris Gailitis.

Addressing power shortages in major European hubs, the 10 MW site, offering up to 250 kW per rack, is built for next-generation workloads, including AI and high-performance computing (HPC). Its modular 6,000 m² layout is fully scalable, with the ability to expand the data center campus site up to 30 MW.

Sustainability is at the core of the design. The facility will run entirely on 100% wind energy, with backup generators powered by Neste MY renewable diesel. Targeting a PUE of just 1.3, it will use advanced free-cooling systems, hot-aisle containment, an effective Weiss Technik wall cooling system and Trane Turbocor-based chillers. It supports both air cooling and high-density direct-to-chip cooling. Delska also aims for LEED green building certification, an achievement held by fewer than 15 buildings in Latvia.

Upon completion, LV DC1 will undergo Tier III Facility certification to confirm its construction and operations meet the same high standard as its design. This will be Delska’s third Tier III-certified data center and sixth overall, joining two Tier III Facility-certified sites in Lithuania. Plans include an additional Lithuanian data center and another facility in the region, strengthening Delska’s Baltic data centers’ network.

About Delska

Delska is one of the largest data center operators in the Baltics, with over 26 years in IT and network infrastructure. Operating fully green Tier III and PCI-DSS certified facilities in Riga and Vilnius with 19 MW capacity, Delska also maintains points of presence in Frankfurt, Amsterdam, and Stockholm. Its portfolio includes cloud, server rental, network, security, and managed services.

Since being acquired by Quaero European Infrastructure Fund II in 2020, Delska has significantly expanded its infrastructure and improved energy efficiency. In 2024, DEAC (Latvia) and DLC (Lithuania) merged under a new Delska brand, and this year RackRay (Lithuania) joined the group of companies.